Cover Image
市場調查報告書

敗血症診斷的全球市場預測 2021年:分子診斷、微生物學、免疫檢測

Sepsis Diagnostics Market by Technology (Molecular Diagnostics, Microbiology, Immunoassay), Product (Instrument, Blood Culture Media), Method (Conventional & Automated), Usability (Laboratory & POC), Pathogen - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 371000
出版日期 內容資訊 英文 176 Pages
訂單完成後即時交付
價格
Back to Top
敗血症診斷的全球市場預測 2021年:分子診斷、微生物學、免疫檢測 Sepsis Diagnostics Market by Technology (Molecular Diagnostics, Microbiology, Immunoassay), Product (Instrument, Blood Culture Media), Method (Conventional & Automated), Usability (Laboratory & POC), Pathogen - Global Forecast to 2021
出版日期: 2016年09月15日 內容資訊: 英文 176 Pages
簡介

全球敗血症診斷的市場規模,預計從2016年到2021年以8.8%的年複合成長率 (CAGR) 發展,至2021年達到5億6,410萬美元。敗血症診斷市場,主要由於全球新生兒、成人人口的敗血症罹患率的增加而受促進。加上老年人口的增加,手術數的增加,院內感染的發病率高,及產品認證數的增加,也支撐著該市場的擴大。 另一方面,標準通訊協定、認識的缺乏,及熟練人員的不足,成為敗血症診斷市場的主要課題。

本報告提供全球敗血症診斷市場相關分析,市場基本結構,主要市場促進、阻礙因素,各市場區隔 (產品、技術、手法、實用性、病原體)的詳細分析,各地區的詳細趨勢,市場競爭的狀態,主要企業簡介等調查、考察。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 重要考察

  • 全球敗血症診斷的富有魅力的市場機會
  • 地區分析:敗血症診斷市場,各產品
  • 敗血症診斷市場規模:各技術
  • 敗血症診斷市場規模:各手法、地區
  • 敗血症診斷市場規模:各實用性
  • 敗血症診斷市場規模:各病原體

第5章 敗血症診斷的全球市場:概要

  • 簡介
  • 市場動態
    • 促進要素
    • 抑制因素
    • 機會
    • 課題

第6章 敗血症診斷的全球市場:各產品

  • 簡介
  • 設備
  • 血液培養基
  • 化驗套件 & 試劑
  • 軟體

第7章 敗血症診斷的全球市場:各技術

  • 簡介
  • 微生物學
  • 分子診斷
  • 免疫檢測
  • 流式細胞技術

第8章 敗血症診斷的全球市場:各手法

  • 簡介
  • 傳統診斷
  • 自動化診斷

第9章 敗血症診斷的全球市場:各硬體設備

  • 簡介
  • 實驗室實驗
  • 照護現場 (POS) 實驗

第10章 敗血症診斷的全球市場:各病原體

  • 簡介
  • 細菌性敗血症
  • 真菌性敗血症
  • 其他病原體感染

第11章 敗血症診斷的全球市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 其他的歐洲 (ROE)
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 其他的亞太地區
  • 其他 (RoW)

第12章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢

第13章 企業簡介

  • 簡介
  • BIOMERIEUX SA
  • BECTON, DICKINSON AND COMPANY
  • THERMO FISHER SCIENTIFIC INC.
  • ABBOTT LABORATORIES, INC.
  • ROCHE DIAGNOSTICS LIMITED (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.)
  • CEPHEID INC.
  • T2 BIOSYSTEMS, INC.
  • BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER CORPORATION)
  • NANOSPHERE, INC. (A LUMINEX COMPANY) 161
  • BRUKER CORPORATION

第14章 附錄

目錄
Product Code: MD 4575

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021.

The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in the neonate and adult population across the globe. In addition, rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and increasing number of product approvals are supporting the growth of this market. On the other hand, lack of standard protocols and awareness as well as shortage of skilled staff are the major challenges in this market.

In this report, the sepsis diagnostics market has been segmented on the basis of product (instruments, blood culture media, assay kits & reagents, and software), technology (microbiology, molecular diagnostics, immunoassays, and flow cytometry), usability (laboratory testing & point-of-care testing), method (conventional diagnostics and automated diagnostics), pathogen (bacterial sepsis, fungal sepsis, and others) and region (North America, Europe, APAC, and RoW). On the basis of products, the blood culture media segment is estimated to account for the largest share of the sepsis diagnostics market in 2016. High use of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis is driving the growth of this segment across the globe.

Geographically, North America (comprising the U.S. and Canada) is expected to command the largest share of the sepsis diagnostics market in 2016, followed by Europe. A number of factors such as the high prevalence of sepsis, increasing number of invasive procedures, growing adoption of high-end sepsis diagnostics devices, and rising government support are contributing to the growth of the North American sepsis diagnostics market. However, lack of standard protocol for sepsis diagnostics and high cost of diagnostic devices are limiting the growth of sepsis diagnostics market in the North America.

The sepsis diagnostics market consists of a large number of big, medium, and small-sized companies. As of 2015, the sepsis diagnostics market was dominated by bioMerieux SA (France), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Cepheid Inc. (U.S.). New product launches and product approvals; partnerships, agreements, and collaborations; and acquisitions; were the major strategies adopted by most of the market players between 2013 and 2016 to achieve growth in the sepsis diagnostics market.

OBJECTIVES OF THE STUDY

  • To define, describe, and forecast the global sepsis diagnostics market on the basis of technology, products, method, usability, pathogen, and region
  • To provide detailed information regarding major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze the micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To provide a five-year forecast for various segments of the sepsis diagnostics market, in terms of revenue, with respect to four main regions, namely, North America (the U.S. and Canada), Europe (Germany, France, the U.K., and Rest of Europe), Asia-Pacific (India, China, Japan, and the Rest of Asia-Pacific), and the Rest of the World
  • To strategically profile the key players and comprehensively analyze their market shares and core competencies2
  • To track and analyze competitive developments such as new product launches,; agreements and partnerships,; and mergers and acquisitions in the global sepsis diagnostics market
  • 1. Micromarkets are defined as the further segments and subsegments of the global sepsis diagnostics market included in the report.
  • 2. Core competencies of the companies are captured in terms of their key developments and key strategies adopted to maintain their market positions.

Target Audience:

  • Sepsis diagnostic device manufacturing companies
  • Clinical laboratories
  • Hospitals and clinics
  • Research institutes and clinical research organizations (CROs)
  • Market research and consulting firms
  • Sepsis diagnostic devices suppliers and distributors
  • Blood culture media manufacturers
  • Blood culture media distributors and suppliers

Scope of the Report:

This research report categorizes the sepsis diagnostics market into the following segments:

Global Sepsis Diagnostics Market, by Technology

  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry

Global Sepsis Diagnostics Market, by Product

  • Blood Culture Media
  • Instruments
  • Assays & Reagents
  • Software

Global Sepsis Diagnostics Market, by Method

  • Conventional Diagnostics
  • Automated Diagnostics

Global Sepsis Diagnostics Market, by Usability

  • Laboratory Testing
  • Point-of-care Testing

Global Sepsis Diagnostics Market, by Pathogen

  • Bacterial Sepsis
  • Gram-negative Bacterial Sepsis
  • Gram-positive Bacterial Sepsis
  • Fungal Sepsis
  • Others

Global Sepsis Diagnostics Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Rest of the World

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
  • 1.4. MARKETS COVERED
    • 1.4.1. YEARS CONSIDERED FOR THE STUDY
  • 1.5. CURRENCY
  • 1.6. LIMITATIONS
  • 1.7. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
    • 2.1.3. MARKET SIZE ESTIMATION METHODOLOGY
      • 2.1.3.1. Bottom-up approach
      • 2.1.3.2. Top-down approach
    • 2.1.4. RESEARCH DESIGN
    • 2.1.5. MARKET DATA VALIDATION AND TRIANGULATION
    • 2.1.6. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. ATTRACTIVE MARKET OPPORTUNITIES IN THE GLOBAL SEPSIS DIAGNOSTICS
  • 4.2. GEOGRAPHIC ANALYSIS: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT
  • 4.3. SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2016 VS. 2021
  • 4.4. SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD AND REGION, 2016
  • 4.5. SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2016 VS 2021
  • 4.6. SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2016 VS 2021

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. High prevalence of sepsis in the neonate and adult population
      • 5.2.1.2. Rising incidence of sepsis in geriatric population
      • 5.2.1.3. Increasing number of preterm births
      • 5.2.1.4. Growing incidence of hospital-acquired infections
      • 5.2.1.5. Increasing number of surgical procedures
      • 5.2.1.6. Growing pneumonia cases
      • 5.2.1.7. Influx of novel sepsis diagnostic products
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High cost of automated diagnostic devices
      • 5.2.2.2. Lack of established reimbursement for sepsis
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Increasing funding for sepsis-related research activities
      • 5.2.3.2. Development of rapid diagnostic techniques for early sepsis diagnosis
      • 5.2.3.3. Evolution of Procalcitonin test as a novel biomarker for sepsis diagnosis
      • 5.2.3.4. Rising initiatives to increase the awareness and drive the adoption of sepsis diagnostic tests
      • 5.2.3.5. Growing number of regulatory approvals for sepsis diagnostic products
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Lack of standard protocols and awareness for sepsis diagnosis and treatment
      • 5.2.4.2. Shortage of skilled healthcare professionals

6. SEPSIS DIAGNOSTICS MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. INSTRUMENTS
  • 6.3. BLOOD CULTURE MEDIA
  • 6.4. ASSAY KITS & REAGENTS
  • 6.5. SOFTWARE

7. SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. MICROBIOLOGY
  • 7.3. MOLECULAR DIAGNOSTICS
  • 7.4. IMMUNOASSAYS
  • 7.5. FLOW CYTOMETRY

8. SEPSIS DIAGNOSTICS MARKET, BY METHOD

  • 8.1. INTRODUCTION
  • 8.2. CONVENTIONAL DIAGNOSTICS
  • 8.3. AUTOMATED DIAGNOSTICS

9. SEPSIS DIAGNOSTICS MARKET, BY USABILITY

  • 9.1. INTRODUCTION
  • 9.2. LABORATORY TESTING
  • 9.3. POINT-OF-CARE TESTING

10. SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN

  • 10.1. INTRODUCTION
  • 10.2. BACTERIAL SEPSIS
    • 10.2.1. GRAM-NEGATIVE BACTERIAL SEPSIS
    • 10.2.2. GRAM-POSITIVE BACTERIAL SEPSIS
  • 10.3. FUNGAL SEPSIS
  • 10.4. OTHER PATHOGEN INFECTIONS

11. SEPSIS DIAGNOSTICS MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. U.S.
      • 11.2.1.1. Growing prevalence of sepsis
      • 11.2.1.2. Increasing incidences of HAIs
      • 11.2.1.3. Increasing government support for sepsis research
      • 11.2.1.4. Growing product approvals
      • 11.2.1.5. Rising initiatives to drive the adoption of sepsis diagnostic tools
      • 11.2.1.6. Lack of standard protocol for sepsis diagnosis hinders market growth
      • 11.2.1.7. High cost of treatment
    • 11.2.2. CANADA
      • 11.2.2.1. Expanding patient population base
      • 11.2.2.2. Support for the development of novel sepsis diagnostic products
      • 11.2.2.3. Growing focus on sepsis management
      • 11.2.2.4. Low awareness related to sepsis management
      • 11.2.2.5. Dearth of training leading to inadequate patient assessment
  • 11.3. EUROPE
    • 11.3.1. GERMANY
      • 11.3.1.1. High incidence of sepsis
      • 11.3.1.2. Growing funding for sepsis research
      • 11.3.1.3. Initiatives by the German Sepsis Society
      • 11.3.1.4. High awareness related to the sepsis management
      • 11.3.1.5. Development of novel sepsis diagnostics products
      • 11.3.1.6. Poor implementation of guidelines related to the sepsis management
    • 11.3.2. U.K.
      • 11.3.2.1. Growing initiatives by government organizations
      • 11.3.2.2. Increasing awareness among medical staff and general practitioners
      • 11.3.2.3. Rising focus towards the development of new sepsis diagnostics devices
      • 11.3.2.4. Rising demand for diagnostic devices
      • 11.3.2.5. Dearth of paramedics
    • 11.3.3. FRANCE
      • 11.3.3.1. Growing number of symposiums and conferences
      • 11.3.3.2. High prevalence of sepsis
      • 11.3.3.3. Growth in research funding for sepsis diagnosis
    • 11.3.4. REST OF EUROPE (ROE)
      • 11.3.4.1. Hub for various sepsis related conferences
      • 11.3.4.2. Rapid growth in the aging population
      • 11.3.4.3. Initiatives to diagnose neonatal sepsis
      • 11.3.4.4. Rising focus on the development of advanced products
  • 11.4. ASIA-PACIFIC
    • 11.4.1. JAPAN
      • 11.4.1.1. Increasing incidence of healthcare-associated infections
      • 11.4.1.2. Growing aging population
      • 11.4.1.3. Increasing initiatives by market players
      • 11.4.1.4. Lack of proper reimbursement for sepsis
    • 11.4.2. CHINA
      • 11.4.2.1. Large number of ongoing clinical studies
      • 11.4.2.2. Developing healthcare infrastructure
      • 11.4.2.3. Limited implementation of Surviving Sepsis Campaign (SSC)
    • 11.4.3. INDIA
      • 11.4.3.1. High sepsis burden
      • 11.4.3.2. Rising antibiotic resistance
      • 11.4.3.3. Rising number of ICU patients
      • 11.4.3.4. Increasing number of surgical procedures
      • 11.4.3.5. Rising focus of local and global players
      • 11.4.3.6. Shortage of medical staff in India
      • 11.4.3.7. Lack of awareness leading to death due to sepsis
    • 11.4.4. REST OF ASIA-PACIFIC
      • 11.4.4.1. Large number of ongoing conferences
      • 11.4.4.2. Rising initiatives to increase awareness about sepsis
      • 11.4.4.3. Significant patient population base in Malaysia
      • 11.4.4.4. South Korea presents significant growth opportunities
      • 11.4.4.5. Lack of established sepsis management guidelines
      • 11.4.4.6. Lack of reimbursement for sepsis
  • 11.5. REST OF THE WORLD
      • 11.5.1.1. Increasing antibiotic resistance among patients
      • 11.5.1.2. Initiatives to improve healthcare in Middle East countries
      • 11.5.1.3. High prevalence of cancer and HIV in the region
      • 11.5.1.4. Key challenges to market growth in the region

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MARKET SHARE ANALYSIS
  • 12.3. COMPETITIVE SITUATION AND TRENDS
    • 12.3.1. PRODUCT APPROVALS
    • 12.3.2. COLLABORATIONS, ACQUISITIONS, AND PARTNERSHIPS
    • 12.3.3. NEW PRODUCT LAUNCHES
    • 12.3.4. OTHER STRATEGIES

13. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 13.1. INTRODUCTION
  • 13.2. BIOMERIEUX SA
  • 13.3. BECTON, DICKINSON AND COMPANY
  • 13.4. THERMO FISHER SCIENTIFIC INC.
  • 13.5. ABBOTT LABORATORIES, INC.
  • 13.6. ROCHE DIAGNOSTICS LIMITED (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.)
  • 13.7. CEPHEID INC.
  • 13.8. T2 BIOSYSTEMS, INC.
  • 13.9. BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER CORPORATION)
  • 13.10. NANOSPHERE, INC. (A LUMINEX COMPANY)
  • 13.11. BRUKER CORPORATION

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. DISCUSSION GUIDE
  • 14.2. OTHER DEVELOPMENTS
  • 14.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.5. AVAILABLE CUSTOMIZATIONS
  • 14.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 2: SEPSIS DIAGNOSTIC INSTRUMENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 3: BLOOD CULTURE MEDIA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: ASSAY KITS & REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 5: SOFTWARE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 6: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 7: MICROBIOLOGY MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: IMMUNOASSAYS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 10: FLOW CYTOMETRY MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 12: CONVENTIONAL DIAGNOSTICS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: AUTOMATED DIAGNOSTIC MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 15: PARAMETERS TESTED IN SEPSIS DIAGNOSIS
  • TABLE 16: LABORATORY TESTING MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: POINT-OF-CARE TESTING MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 19: BACTERIAL SEPSIS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 20: BACTERIAL SEPSIS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 21: FUNGAL SEPSIS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: OTHER PATHOGEN INFECTIONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: SEPSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 25: NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 26: NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 27: NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 28: NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 29: NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 30: U.S.: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 31: U.S.: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 32: U.S.: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 33: U.S.: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 34: U.S.: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 35: CANADA: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 36: CANADA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 37: CANADA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 38: CANADA: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 39: CANADA: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 40: EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 41: EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 42: EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 43: EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 44: EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 45: EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 46: GERMANY: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 47: GERMANY: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 48: GERMANY: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 49: GERMANY: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 50: GERMANY: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 51: U.K.: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 52: U.K.: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 53: U.K.: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 54: U.K.: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 55: U.K.: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 56: FRANCE: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 57: FRANCE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 58: FRANCE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 59: FRANCE: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 60: FRANCE: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 61: ROE: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 62: ROE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 63: ROE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 64: ROE: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 65: ROE: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 66: APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 67: APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 68: APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 69: APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 70: APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 71: APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 72: JAPAN: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 73: JAPAN: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 74: JAPAN: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 75: JAPAN: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 76: JAPAN: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 77: CHINA: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 78: CHINA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 79: CHINA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 80: CHINA: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 81: CHINA: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 82: INDIA: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 83: INDIA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 84: INDIA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 85: INDIA: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 86: INDIA: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 87: ROAPAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 88: ROAPAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 89: ROAPAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 90: ROAPAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 91: ROAPAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 92: ROW: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 93: ROW: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 94: ROW: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION)
  • TABLE 95: ROW: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 96: ROW: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION)
  • TABLE 97: TOP 5 PRODUCT APPROVALS, 2013-2016
  • TABLE 98: TOP 5 COLLABORATIONS, ACQUISITION, AND PARTNERSHIPS, 2013-2016
  • TABLE 99: TOP 4 NEW PRODUCT LAUNCHES, 2013-2016
  • TABLE 100: TOP 5 OTHER STRATEGIES, 2013-2016

LIST OF FIGURES

  • FIGURE 1: SEPSIS DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2: GLOBAL SEPSIS DIAGNOSTICS MARKET: RESEARCH METHODOLOGY STEPS
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2016
  • FIGURE 7: GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016 (USD MILLION)
  • FIGURE 8: GLOBAL SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2016 VS. 2021
  • FIGURE 9: GLOBAL SEPSIS DIAGNOSTICS MARKET, BY USABILITY, 2016 VS. 2021
  • FIGURE 10: GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2016 VS. 2021
  • FIGURE 11: GLOBAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2016 (USD MILLION)
  • FIGURE 12: INCREASING PREVALENCE OF SEPSIS-PRIMARY DRIVER OF THE SEPSIS DIAGNOSTICS MARKET
  • FIGURE 13: BLOOD CULTURE MEDIA SEGMENT TO DOMINATE THE GLOBAL SEPSIS DIAGNOSTICS MARKET IN 2016
  • FIGURE 14: MICROBIOLOGY SEGMENT WILL CONTINUE TO DOMINATE THE SEPSIS DIAGNOSTICS MARKET IN 2021
  • FIGURE 15: CONVENTIONAL DIAGNOSTICS SEGMENT TO DOMINATE THE GLOBAL SEPSIS DIAGNOSTICS MARKET IN 2016
  • FIGURE 16: LABORATORY TESTING SEGMENT TO DOMINATE THE GLOBAL SEPSIS DIAGNOSTICS MARKET IN 2016
  • FIGURE 17: BACTERIAL SEPSIS SEGMENT TO DOMINATE THE GLOBAL SEPSIS DIAGNOSTICS MARKET IN 2016
  • FIGURE 18: SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19: CHANCES OF DEVELOPING SEPSIS INCREASE WITH AGE, 2014
  • FIGURE 20: PATIENT SURVIVAL RATE IN SEPSIS CASES
  • FIGURE 21: BLOOD CULTURE MEDIA SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD (2016- 2021)
  • FIGURE 22: NORTH AMERICA TO DOMINATE THE INSTRUMENTS MARKET IN 2016
  • FIGURE 23: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE BLOOD CULTURE MEDIA MARKET, 2016
  • FIGURE 24: NORTH AMERICA TO DOMINATE THE ASSAY KITS & REAGENTS MARKET IN 2016
  • FIGURE 25: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE SOFTWARE SEGMENT (2016-2021)
  • FIGURE 26: MOLECULAR DIAGNOSTICS SEGMENT TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD (2016-2021)
  • FIGURE 27: NORTH AMERICA TO DOMINATE THE MICROBIOLOGY MARKET IN 2016
  • FIGURE 28: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE MOLECULAR DIAGNOSTICS MARKET IN 2016
  • FIGURE 29: NORTH AMERICA TO DOMINATE THE IMMUNOASSAYS MARKET IN 2016
  • FIGURE 30: NORTH AMERICA TO DOMINATE THE FLOW CYTOMETRY MARKET IN 2016
  • FIGURE 31: CONVENTIONAL DIAGNOSTICS SEGMENT WILL CONTINUE TO DOMINATE THE SEPSIS DIAGNOSTICS MARKET IN 2021
  • FIGURE 32: NORTH AMERICA TO DOMINATE THE CONVENTIONAL DIAGNOSTICS MARKET IN 2016
  • FIGURE 33: ASIA-PACIFIC TO WITNESS HIGH GROWTH IN THE AUTOMATED DIAGNOSTICS SEGMENT DURING THE FORECAST PERIOD, 2016-2021
  • FIGURE 34: POCT SEGMENT TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD, 2016-2021
  • FIGURE 35: NORTH AMERICA TO DOMINATE THE LABORATORY TESTING MARKET IN 2016
  • FIGURE 36: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE POINT-OF-CARE TESTING SEGMENT (2016-2021)
  • FIGURE 37: BACTERIAL SEPSIS SEGMENT TO WITNESS HIGHEST GROWTH, 2016-2021
  • FIGURE 38: GRAM-NEGATIVE BACTERIA SEGMENT TO DOMINATE THE BACTERIAL SEPSIS MARKET IN 2016
  • FIGURE 39: ASIA-PACIFIC TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD, (2016-2021)
  • FIGURE 40: NORTH AMERICA TO DOMINATE THE FUNGAL SEPSIS MARKET IN 2016
  • FIGURE 41: ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE OTHER PATHOGENS SEGMENT IN 2016
  • FIGURE 42: SEPSIS DIAGNOSTICS MARKET: GROWTH FORECAST, BY REGION (2016-2021)
  • FIGURE 43: NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 44: EUROPE: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 45: APAC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 46: GLOBAL SEPSIS DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 47: BATTLE FOR MARKET SHARE: PRODUCT APPROVALS THE KEY STRATEGY
  • FIGURE 48: GEOGRAPHIC REVENUE MIX OF THE TOP PLAYERS
  • FIGURE 49: BIOMERIEUX SA: COMPANY SNAPSHOT
  • FIGURE 50: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 51: THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • FIGURE 52: ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 53: ROCHE DIAGNOSTICS LIMITED: COMPANY SNAPSHOT
  • FIGURE 54: CEPHEID: COMPANY SNAPSHOT
  • FIGURE 55: T2 BIOSYSTEMS, INC.: COMPANY SNAPSHOT
  • FIGURE 56: DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 57: LUMINEX CORPORATION: COMPANY SNAPSHOT
  • FIGURE 58: BRUKER CORPORATION: COMPANY SNAPSHOT
Back to Top